CRISPR Therapeutics AG

The company is a biopharmaceutical firm that develops gene-based medicines using CRISPR/Cas9 gene-editing technology. It operates across four primary areas: hemoglobinopathies, in vivo editing, CAR T cell therapies, and regenerative medicine. Its approved therapy, CASGEVY, co-developed with Vertex Pharmaceuticals, treats severe sickle cell disease and transfusion-dependent beta thalassemia. Other investigational candidates address cardiovascular conditions, autoimmune disorders, cancers, and Type 1 diabetes. Its end users are patients suffering from severe genetic, hematologic, oncologic, and metabolic diseases.

Its approved therapy is authorized in the United States, the European Union, Great Britain, Canada, Switzerland, and Middle Eastern countries including Saudi Arabia, Bahrain, Qatar, the United Arab Emirates, and Kuwait. The company operates a manufacturing facility in Framingham, Massachusetts, to produce investigational cell therapies, and engages in clinical collaborations across the United States and Greater China. The provided text does not state the location of the company's headquarters.

Summary of the business section of CRISPR Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2024, we had 393 full-time employees.”